{"filing":{"accession_number":"0001776985-26-000061","cik":"0001776985","ticker":"BNTX","company_name":"BioNTech SE","form":"6-K","filing_date":"2026-08-28","report_date":"2026-08-28","primary_document":"form6-kcrc28aug2026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1776985/000177698526000061/form6-kcrc28aug2026.htm"},"events":[{"id":30223,"run_id":27707,"accession_number":"0001776985-26-000061","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"BioNTech announced termination of the Phase 2 clinical trial BNT122-01 for autogene cevumeran in colorectal cancer following a Data Safety Monitoring Board recommendation due to a numerical imbalance in overall survival and low likelihood of efficacy. This is a material operational/clinical development event affecting a key pipeline program, though it does not fit the specific categories of exec changes, M\u0026A, impairment, or litigation. The decision reflects a significant setback in the company's oncology strategy and would affect investor assessment of pipeline prospects.","company_name":"BioNTech SE","ticker":"BNTX","filing_date":"2026-08-28","form":"6-K","submitted_at":null,"items":[{"id":32764,"accession_number":"0001776985-26-000061","item_number":"EX-99.1","item_title":"a991260828_bntxxcrcxenxfin.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"BioNTech announced termination of the Phase 2 clinical trial BNT122-01 for autogene cevumeran in colorectal cancer following a Data Safety Monitoring Board recommendation due to a numerical imbalance in overall survival and low likelihood of efficacy. This is a material operational/clinical development event affecting a key pipeline program, though it does not fit the specific categories of exec changes, M\u0026A, impairment, or litigation. The decision reflects a significant setback in the company's oncology strategy and would affect investor assessment of pipeline prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-28T13:09:38.016271+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32764,"accession_number":"0001776985-26-000061","item_number":"EX-99.1","item_title":"a991260828_bntxxcrcxenxfin.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"BioNTech announced termination of the Phase 2 clinical trial BNT122-01 for autogene cevumeran in colorectal cancer following a Data Safety Monitoring Board recommendation due to a numerical imbalance in overall survival and low likelihood of efficacy. This is a material operational/clinical development event affecting a key pipeline program, though it does not fit the specific categories of exec changes, M\u0026A, impairment, or litigation. The decision reflects a significant setback in the company's oncology strategy and would affect investor assessment of pipeline prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-28T13:09:38.016271+00:00","company_name":"BioNTech SE","ticker":"BNTX","filing_date":"2026-08-28"}]}